Skip to main content
SpringerLink
Log in
Book cover

TNF-alpha Inhibitors pp 9–22Cite as

History of development of TNF inhibitors

  • Chapter

Part of the book series: Milestones in Drug Therapy ((MDT))

Concluding remarks

Advancements in anti-cytokine therapy have been heralded as a new era in the treatment of autoimmune diseases. Insights gained from the development of TNF inhibitors have helped pave the way for the development of other anticytokine therapies, which are now in various phases of clinical trials. The success of TNF inhibitors in treating a number of inflammatory illnesses has greatly advanced our understanding of the mechanisms underlying the pathogenesis of these diseases, and raised expectations about the potential for longterm abatement and control of diseases such as moderate to severe RA and psoriasis. Because of these advancements, anti-TNF-α therapies are currently being investigated in patients with other chronic conditions, including congestive heart failure, vasculitis, Behcet’s disease, hepatitis, and dermatomyositis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M (2002) Cytokines and anticytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 13: 299–313

    Article  PubMed  CAS  Google Scholar 

  2. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163–196

    Article  PubMed  CAS  Google Scholar 

  3. Arend WP, Dayer JM (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38: 151–160

    PubMed  CAS  Google Scholar 

  4. Asadullah K, Sterry W, Volk HD (2002) Analysis of cytokine expression in dermatology. Arch Dermatol 138: 1189–1196

    Article  PubMed  CAS  Google Scholar 

  5. Feldmann M, Maini RN (2002) Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 69: 12–18

    Article  PubMed  Google Scholar 

  6. Borish LC, Steinke JW (2003) 2. Cytokines and chemokines. J Allergy Clin Immunol 111: S460–S475

    Article  PubMed  CAS  Google Scholar 

  7. van den Berg WB (2001) Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 3: 18–26

    Article  PubMed  Google Scholar 

  8. Aggarwal BB, Aiyer RA, Pennica D, Gray PW, Goeddel DV (1987) Human tumour necrosis factors: structure and receptor interactions. Ciba Found Symp 131: 39–51

    PubMed  CAS  Google Scholar 

  9. Haranaka K, Carswell EA, Williamson BD, Prendergast JS, Satomi N, Old LJ (1986) Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci USA 83: 3949–3953

    Article  PubMed  CAS  Google Scholar 

  10. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddel DV (1985) Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 82: 6060–6064

    Article  PubMed  CAS  Google Scholar 

  11. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45–53

    Article  PubMed  CAS  Google Scholar 

  12. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D et al (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733–736

    Article  PubMed  CAS  Google Scholar 

  13. Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G (1989) Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 42: 270–275

    Article  PubMed  CAS  Google Scholar 

  14. Seckinger P, Isaaz S, Dayer JM (1988) A human inhibitor of tumor necrosis factor alpha. J Exp Med 167: 1511–1516

    Article  PubMed  CAS  Google Scholar 

  15. Heim ME, Siegmund R, Illiger HJ, Klee M, Rieche K, Berdel WE, Edler L (1990) Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 13: 444–447

    Article  PubMed  CAS  Google Scholar 

  16. Lenk H, Tanneberger S, Muller U, Ebert J, Shiga T (1989) Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 24: 391–392

    Article  PubMed  CAS  Google Scholar 

  17. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487–501

    Article  PubMed  CAS  Google Scholar 

  18. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959–962

    Article  PubMed  CAS  Google Scholar 

  19. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673–682

    Article  PubMed  CAS  Google Scholar 

  20. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS (1989) Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 86: 2365–2368

    Article  PubMed  CAS  Google Scholar 

  21. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anticachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330: 662–664

    Article  PubMed  CAS  Google Scholar 

  22. Enbrel® (etanercept) [package insert]. Thousand Oaks, Calif. Amgen Inc. and Wyeth-Ayerst Pharmaceuticals, 2004

    Google Scholar 

  23. Remicade® (infliximab) [package insert]. Malvern, Pa. Centacor Inc., 2003

    Google Scholar 

  24. Humira® (adalimumab) [package insert]. North Chicago, Ill. Abbott Laboratories, 2003

    Google Scholar 

  25. Kaushansky K, Broudy VC, Harlan JM, Adamson JW (1988) Tumor necrosis factor-alpha and tumor necrosis factor-beta (lymphotoxin) stimulate the production of granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and IL-1 in vivo. J Immunol 141: 3410–3415

    PubMed  CAS  Google Scholar 

  26. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, Dower SK, Cosman D, Goodwin RG (1990) A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019–1023

    PubMed  CAS  Google Scholar 

  27. Jacobs CA, Sims JE, Mohler KM, Dower S, Giri JG, Smith CA, Mullarkey MF (1994) Soluble cytokine receptors as potential therapeutic antagonists. In: M Freund, H Link, RE Schmidt, K Welte, (eds): Cytokines in Hemopoiesis, Oncology, and Immunology III. Springer Verlag, Berlin, 453–460

    Google Scholar 

  28. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM (1997) DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 159: 2867–2876

    PubMed  CAS  Google Scholar 

  29. Alexopoulou L, Pasparakis M, Kollias G (1997) A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 27: 2588–2592

    PubMed  CAS  Google Scholar 

  30. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77: 510–514

    PubMed  CAS  Google Scholar 

  31. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89: 7375–7379

    Article  PubMed  CAS  Google Scholar 

  32. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784–9788

    Article  PubMed  CAS  Google Scholar 

  33. Semmler J, Wachtel H, Endres S (1993) The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 15: 409–413

    Article  PubMed  CAS  Google Scholar 

  34. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S (1995) Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 25: 147–153

    PubMed  CAS  Google Scholar 

  35. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675–1680

    Article  PubMed  CAS  Google Scholar 

  36. Aggarwal BB, Schwarz L, Hogan ME, Rando RF (1996) Triple helix-forming oligodeoxyribonu-cleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. Cancer Res 56: 5156–5164

    PubMed  CAS  Google Scholar 

  37. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM (1996) Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J Clin Invest 97: 2833–2841

    Article  PubMed  CAS  Google Scholar 

  38. Kohno T, Stevens S, Louie J (2005) Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation: A different mechanism from etanercept. [Abstract]. J Am Acad Dermatol 52: 36

    Google Scholar 

  39. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30: 1443–1453

    Article  PubMed  CAS  Google Scholar 

  40. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 156: 1646–1653

    PubMed  CAS  Google Scholar 

  41. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7: 251–259

    Article  PubMed  CAS  Google Scholar 

  42. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105–1110

    Article  PubMed  CAS  Google Scholar 

  43. Moreland LW (1998) Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 24: 579–591

    Article  PubMed  CAS  Google Scholar 

  44. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337: 1029–1035

    Article  PubMed  CAS  Google Scholar 

  45. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088–1094

    Article  PubMed  CAS  Google Scholar 

  46. Dinarello CA (2005) Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl 74: 40–47

    PubMed  CAS  Google Scholar 

  47. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA (2004) Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 31: 2356–2359

    PubMed  CAS  Google Scholar 

  48. van Vollenhoven RF (2004) Switching between biological agents. Clin Exp Rheumatol 22: S115–S121

    PubMed  Google Scholar 

  49. Fisher CJ, Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697–1702

    Article  PubMed  CAS  Google Scholar 

  50. Davis JC, Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48: 3230–3236

    Article  PubMed  CAS  Google Scholar 

  51. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A et al (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139: 1627–1632; discussion 1632

    Article  PubMed  CAS  Google Scholar 

  52. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubleblind randomised controlled trial. Lancet 363: 675–681

    Article  PubMed  CAS  Google Scholar 

  53. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342: 763–769

    Article  PubMed  CAS  Google Scholar 

  54. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50: 2264–2272

    Article  PubMed  CAS  Google Scholar 

  55. Clinical Trials.gov Web Site (Accessed March 28, 2005) Onercept in the Treatment and Re-Treatment of Subjects with Moderate to Severe Plaque Psoriasis. At: http://www.clinicaltrials.gov/ct/gui/show/NCT00090129?order=1

    Google Scholar 

  56. Furst DE, Weisman M, Paulus HE, Bulpitt K, Weinblatt M, Polisson R, Zaug M, Kneer J, Van der Auwera P, Stevens RM (2003) Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J Rheumatol 30: 2123–2126

    PubMed  CAS  Google Scholar 

  57. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger EJ, Grau G, Piguet PF, Pointaire P, Vassalli P, Loetscher H (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21: 2883–2886

    PubMed  CAS  Google Scholar 

  58. Fernandez-Botran R (2000) Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Investig Drugs 9: 497–514

    Article  PubMed  CAS  Google Scholar 

  59. Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J et al (2001) Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis Res 3: 247–252

    Article  PubMed  CAS  Google Scholar 

  60. Asadullah K, Docke WD, Ebeling M, Friedrich M, Belbe G, Audring H, Volk HD, Sterry W (1999) Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial. Arch Dermatol 135: 187–192

    Article  PubMed  CAS  Google Scholar 

  61. Trepicchio WL, Ozawa M, Walters IB, Kikuchi T, Gilleaudeau P, Bliss JL, Schwertschlag U, Dorner AJ, Krueger JG (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104: 1527–1537

    PubMed  CAS  Google Scholar 

  62. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD (1998) Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 134: 799–804

    Article  PubMed  CAS  Google Scholar 

  63. Panitch H, Miller A, Paty D, Weinshenker B (2004) Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63: 1788–1795

    PubMed  Google Scholar 

  64. Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13: 323–340

    Article  PubMed  CAS  Google Scholar 

  65. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA, Jr, O’Connor JV (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 163: 1433–1450

    Article  PubMed  CAS  Google Scholar 

  66. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y (2000) Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 191: 313–320

    Article  PubMed  CAS  Google Scholar 

  67. van den Berg WB, Joosten LA, van de Loo FA (1999) TNF alpha and IL-1 beta are separate targets in chronic arthritis. Clin Exp Rheumatol 17: S105–S114

    PubMed  Google Scholar 

  68. Kineret? (anakinra) [package insert]. Thousand Oaks, Calif. Amgen Inc., 2002

    Google Scholar 

  69. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, Hayden K, Jagannath S, Barlogie B (1994) Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330: 602–605

    Article  PubMed  CAS  Google Scholar 

  70. Gringeri A, Santagostino E, Cusini M, Muca-Perja M, Marinoni A, Mannucci PM, Burny A, Criscuolo M, Lu W, Andrieru JM et al (1996) Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. J Acquir Immune Defic Syndr Hum Retrovirol 13: 55–67

    Article  PubMed  CAS  Google Scholar 

  71. Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (2002) Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130: 93–100

    Article  PubMed  CAS  Google Scholar 

  72. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R et al (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148

    Article  PubMed  CAS  Google Scholar 

  73. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, Alcocer-Varela J, Grangeot-Keros L, Alarcon-Segovia D, Wijdenes J et al (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790–1800

    Article  PubMed  CAS  Google Scholar 

  74. Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A (2002) Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 13: 429–439

    Article  PubMed  CAS  Google Scholar 

  75. Plater-Zyberk C, Joosten LA, Helsen MM, Sattonnet-Roche P, Siegfried C, Alouani S, van De Loo FA, Graber P, Aloni S, Cirillo R et al (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108: 1825–1832

    Article  PubMed  CAS  Google Scholar 

  76. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432–3443

    Article  PubMed  CAS  Google Scholar 

  77. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52: 582–591

    Article  PubMed  CAS  Google Scholar 

  78. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35–45

    Article  PubMed  CAS  Google Scholar 

  79. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41: 1133–1137

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amgen, Thousand Oaks, California, USA

    Seth R. Stevens & Ting H. Chang

Authors
  1. Seth R. Stevens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ting H. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY, 10025, USA

    Jeffrey M. Weinberg  & Robin Buchholz  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Stevens, S.R., Chang, T.H. (2006). History of development of TNF inhibitors. In: Weinberg, J.M., Buchholz, R. (eds) TNF-alpha Inhibitors. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7438-1_2

Download citation

Publish with us

Policies and ethics

Search

Navigation